Straight Answers. No Fluff.

Bold You programs use compounded semaglutide and compounded tirzepatide prescribed by licensed clinicians. Medication decisions are individualized after your provider reviews goals, history, and risk profile. Dispensing is handled through FDA-registered 503A/503B compounding pharmacy partners.

Semaglutide acts on GLP-1 pathways, while tirzepatide targets GLP-1 and GIP pathways. Both can be effective depending on your metabolic profile, goals, and tolerance. Your provider recommends the best fit rather than using a one-size-fits-all default.

Microdosing uses lower-dose pathways for appetite management, metabolic support, and maintenance-focused outcomes. It can be relevant for patients who do not need or want standard higher-dose progression. Eligibility is always provider-determined after clinical review.

The model combines telehealth evaluation, prescribing, medication fulfillment, and coaching in one continuous workflow. Patients often avoid repeated office scheduling and insurance friction while still receiving licensed provider oversight. The program is built for consistency, not one-time visits.

You can contact care support through the portal for clinical guidance and escalation. Providers can adjust titration pace, timing, and supportive strategies when appropriate. If symptoms are urgent or severe, seek emergency care immediately.

Labs may be ordered when clinically appropriate by your treating provider. Decisions depend on your pathway, medical history, and state-specific requirements. Lab data is used to improve treatment precision and safety.

Some patients with diabetes may qualify, depending on current medications and risk factors. Provider review is required to determine safety and fit. Not every program is appropriate for every patient profile.

TRT options may be available in men's health pathways where clinically indicated and compliant in your state. Providers may require additional evaluation, including labs, before treatment decisions. All prescribing remains clinician-led.

No insurance is required. The direct-pay model helps patients avoid prior authorization delays and denials. Many patients use credit cards, and eligible plans can often use HSA/FSA payment methods.

Plan pricing is structured to remain predictable rather than automatically changing with each dose adjustment. This helps reduce billing surprises during titration. Any plan-level changes are communicated before they take effect.

Depending on your state and provider assessment, hormone-focused options may be available without a GLP-1-first pathway. Clinical fit is reviewed individually rather than assumed. Availability can vary based on regulations and protocol eligibility.

Once approved by your provider, your order moves into pharmacy fulfillment and shipping. Many patients receive medication within roughly 5-7 business days after approval. Exact timelines can vary by location and shipping conditions.

The provider network supports all 50 states. State-specific telehealth and prescribing requirements still apply to each case. Your intake is routed according to local clinical compliance rules.

Month-to-month accounts can generally cancel according to policy terms in the member portal. Eligible programs may also support pause options under specific conditions. Terms are provided clearly at enrollment.

Coaching sessions focus on adherence, appetite strategy, side-effect management, and consistency habits. Cadence depends on plan level, typically monthly or bi-weekly. The goal is to improve long-term retention and outcomes.

Your provider can transition you into a maintenance-oriented strategy based on your progress and risk profile. Coaching then shifts toward relapse prevention and sustainable routines. The objective is preserving results, not only achieving them.